ALSP Orchid Acquisition Corporation I
ALORW
NASDAQ Global Market0.00
USD
+0.00
- -
CIK
0001883962
CUSIP
G0231L123
Return %
Stock
S&P500
1Y
-96.20
26.53
3Y
-99.54
76.60
5Y
-99.54
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Thong Q. Le
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 2815 Eastlake Avenue East Seattle WA United States of America 98102
- IPO Date
- Jan 10, 2022
- CIK
- 0001883962
- Similar Companies
- Business
- ALSP Orchid Acquisition Corporation I is a special purpose acquisition company (SPAC) formed in 2021 and headquartered in Seattle, Washington. The company does not have significant operations of its own but is established to effect mergers, share exchanges, asset acquisitions, share purchases, reorganizations, or similar business combinations, primarily targeting life science companies in North America and Singapore. It is formed by Accelerator Life Science Partners and leverages an experienced management team with expertise in healthcare, biotechnology, and life sciences sectors. ALSP Orchid's business model focuses on identifying and acquiring companies developing assets and next-generation platform technologies with broad applicability within the life sciences industry. Recently, ALSP Orchid announced that it would redeem its public shares and will not consummate an initial business combination within the required timeframe, leading to the cessation of its operations except for winding up its business, signaling a major operational conclusion within the past year. The company is affiliated with ALSP Orchid Sponsor LLC and has positioned itself as a blank check vehicle with a strategic emphasis on healthcare and life sciences acquisitions, although it has yet to complete an acquisition or generate revenue. Its primary products and services revolve around facilitating capital market transactions and investment opportunities in life sciences through merger and acquisition activities rather than direct product manufacturing or service provision.